NM_021098.3:c.4023G>A
Variant names:
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_021098.3(CACNA1H):c.4023G>A(p.Ala1341Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0593 in 1,605,038 control chromosomes in the GnomAD database, including 3,332 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.047 ( 249 hom., cov: 33)
Exomes 𝑓: 0.061 ( 3083 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
3
Clinical Significance
Conservation
PhyloP100: -2.34
Publications
4 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 16-1210636-G-A is Benign according to our data. Variant chr16-1210636-G-A is described in ClinVar as Benign. ClinVar VariationId is 585639.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-2.34 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.0766 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CACNA1H | NM_021098.3 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | ENST00000348261.11 | NP_066921.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 34 | 1 | ENSP00000454990.2 | |||
| CACNA1H | ENST00000711493.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 34 | ENSP00000518778.1 | ||||
| CACNA1H | ENST00000565831.7 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 34 | 1 | ENSP00000455840.1 | |||
| CACNA1H | ENST00000711450.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | ENSP00000518762.1 | ||||
| CACNA1H | ENST00000564231.6 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | 1 | ENSP00000457555.2 | |||
| CACNA1H | ENST00000638323.1 | c.3984G>A | p.Ala1328Ala | synonymous_variant | Exon 20 of 35 | 5 | ENSP00000492267.1 | |||
| CACNA1H | ENST00000562079.6 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 34 | 1 | ENSP00000454581.2 | |||
| CACNA1H | ENST00000711438.1 | c.3984G>A | p.Ala1328Ala | synonymous_variant | Exon 20 of 34 | ENSP00000518754.1 | ||||
| CACNA1H | ENST00000711482.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 36 | ENSP00000518771.1 | ||||
| CACNA1H | ENST00000711485.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | ENSP00000518774.1 | ||||
| CACNA1H | ENST00000711455.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 36 | ENSP00000518768.1 | ||||
| CACNA1H | ENST00000711483.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 35 | ENSP00000518772.1 | ||||
| CACNA1H | ENST00000711456.1 | c.4023G>A | p.Ala1341Ala | synonymous_variant | Exon 20 of 34 | ENSP00000518769.1 | ||||
| CACNA1H | ENST00000621827.2 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 37 | 6 | ENSP00000518766.1 | ||||
| CACNA1H | ENST00000637236.3 | n.4073G>A | non_coding_transcript_exon_variant | Exon 20 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*1936G>A | non_coding_transcript_exon_variant | Exon 20 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*3470G>A | non_coding_transcript_exon_variant | Exon 19 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711484.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 35 | ENSP00000518773.1 | |||||
| CACNA1H | ENST00000711486.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 37 | ENSP00000518775.1 | |||||
| CACNA1H | ENST00000711487.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 36 | ENSP00000518776.1 | |||||
| CACNA1H | ENST00000711488.1 | n.4023G>A | non_coding_transcript_exon_variant | Exon 20 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000640028.1 | n.*1936G>A | 3_prime_UTR_variant | Exon 20 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*3470G>A | 3_prime_UTR_variant | Exon 19 of 34 | ENSP00000518758.1 |
Frequencies
GnomAD3 genomes AF: 0.0471 AC: 7160AN: 152140Hom.: 248 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
7160
AN:
152140
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0553 AC: 13321AN: 241058 AF XY: 0.0592 show subpopulations
GnomAD2 exomes
AF:
AC:
13321
AN:
241058
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0606 AC: 87993AN: 1452780Hom.: 3083 Cov.: 40 AF XY: 0.0618 AC XY: 44693AN XY: 722948 show subpopulations
GnomAD4 exome
AF:
AC:
87993
AN:
1452780
Hom.:
Cov.:
40
AF XY:
AC XY:
44693
AN XY:
722948
show subpopulations
African (AFR)
AF:
AC:
286
AN:
33472
American (AMR)
AF:
AC:
1443
AN:
44676
Ashkenazi Jewish (ASJ)
AF:
AC:
2444
AN:
26120
East Asian (EAS)
AF:
AC:
11
AN:
39688
South Asian (SAS)
AF:
AC:
7455
AN:
86198
European-Finnish (FIN)
AF:
AC:
2339
AN:
44962
Middle Eastern (MID)
AF:
AC:
485
AN:
5766
European-Non Finnish (NFE)
AF:
AC:
69871
AN:
1111616
Other (OTH)
AF:
AC:
3659
AN:
60282
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
4997
9994
14992
19989
24986
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
2480
4960
7440
9920
12400
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0470 AC: 7161AN: 152258Hom.: 249 Cov.: 33 AF XY: 0.0457 AC XY: 3405AN XY: 74458 show subpopulations
GnomAD4 genome
AF:
AC:
7161
AN:
152258
Hom.:
Cov.:
33
AF XY:
AC XY:
3405
AN XY:
74458
show subpopulations
African (AFR)
AF:
AC:
393
AN:
41558
American (AMR)
AF:
AC:
665
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
AC:
318
AN:
3472
East Asian (EAS)
AF:
AC:
7
AN:
5182
South Asian (SAS)
AF:
AC:
402
AN:
4828
European-Finnish (FIN)
AF:
AC:
528
AN:
10610
Middle Eastern (MID)
AF:
AC:
26
AN:
294
European-Non Finnish (NFE)
AF:
AC:
4550
AN:
67988
Other (OTH)
AF:
AC:
118
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
352
704
1057
1409
1761
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
80
160
240
320
400
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
108
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Nov 22, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.